Furol

Quick links to important sections

Furol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furol

What is Furol?

Furol is a pharmaceutical formulation containing the active substance furosemide. It belongs to a group of medications known as loop diuretics, which are primarily used to manage fluid retention and certain cardiovascular conditions.

Mechanism of Action

The primary function of Furol is to promote the excretion of excess fluid and salts from the body. It achieves this by acting on the kidneys, specifically within a structure called the loop of Henle. By inhibiting the reabsorption of sodium and chloride, the medication increases the amount of urine produced. This process helps to reduce the volume of fluid circulating in the bloodstream and within the body's tissues.

Therapeutic Use

Furol is typically utilized in the management of edema, a condition characterized by the accumulation of fluid in the tissues. This swelling is often associated with underlying medical issues such as:

  • Congestive Heart Failure: Where the heart's pumping ability is compromised, leading to fluid buildup in the lungs or extremities.
  • Liver Disease: Specifically cirrhosis, which can cause fluid to collect in the abdomen or legs.
  • Renal Disease: Conditions where the kidneys are unable to maintain a proper balance of fluids and electrolytes.

In addition to treating edema, Furol may be used in the management of hypertension. By reducing the total fluid volume in the vascular system, it can help lower blood pressure levels in patients for whom this treatment is appropriate.

Regulatory References

  1. NIH: Clinical Pharmacology of Bromopride

What side effects are possible with Furol?

Possible Side Effects and Safety Information

Furol, a fluoroquinolone antibiotic, is associated with a risk of serious, potentially disabling, and long-lasting or irreversible side effects affecting multiple body systems, as communicated by health regulatory authorities.

Serious and Clinically Significant Adverse Reactions

The FDA has issued its strongest caution, a Boxed Warning, regarding these systemic risks. The serious adverse effects can manifest in different body systems, sometimes occurring together in the same patient, and may appear within hours to weeks of beginning treatment, or even after discontinuation. These include:

  • Musculoskeletal and Peripheral Nervous System: Tendinitis and tendon rupture (most commonly Achilles tendon rupture), joint pain/swelling, muscle pain/weakness, and peripheral neuropathy (nerve damage, often presenting as burning, numbness, or tingling sensations in the limbs).
  • Central Nervous System (CNS) and Mental Health: Disturbances in attention, anxiety, depression, memory impairment, confusion, psychosis, hallucinations, and suicidal thoughts.
  • Cardiovascular: Prolongation of the QT interval on the electrocardiogram, which can lead to abnormal heart rhythms (arrhythmias).
  • Other Serious Effects: Worsening of myasthenia gravis, severe hypersensitivity (allergic) reactions, and significant blood sugar disturbances (both high and life-threatening low blood sugar, which can lead to a coma).

Safety Restrictions and Monitoring

Due to the severity of these potential reactions, regulatory bodies advise that Furol be reserved for patients who have no other available treatment options for certain uncomplicated bacterial infections (e.g., acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections). The risk of adverse events may be higher in the elderly, those with kidney impairment, or those receiving corticosteroid therapy. Patients should be monitored for any signs of tendon, nerve, or CNS symptoms.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Furol (Bromopride) can result in serious clinical manifestations affecting the neurological and cardiovascular systems, as documented in official regulatory profiles.

Clinical Manifestations and Severe Outcomes

Neurological overdose presentations include signs of Central Nervous System (CNS) Depression, such as excessive drowsiness, confusion, and somnolence. A critical manifestation is the onset of Extrapyramidal Symptoms (EPS), which are characterized by involuntary movements and muscle rigidity, particularly in children and young adults.

Life-threatening outcomes officially documented in the drug class include severe cardiovascular events such as severe bradycardia, circulatory collapse, and cardiac arrest. The risk of Neuroleptic Malignant Syndrome (NMS) and the physiological finding of QT prolongation are also noted in regulatory information.

When to Seek Immediate Medical Help

Immediate medical attention must be sought for any suspected overdose. The product must be discontinued immediately upon the appearance of neurological signs such as EPS. Because no specific antidote is known, management focuses on symptomatic and supportive treatment.

Hospitalization is required to provide continuous monitoring, which includes Electrocardiogram (ECG) monitoring to assess for cardiac electrical disturbances. Treatment for EPS typically involves supportive agents such as benzodiazepines or anticholinergic medicinal products, as outlined in official management protocols.

Therapeutic Uses of Furol

Furol (Bromopride) is used in cases where additional symptomatic support is needed for upper digestive discomfort. It is utilized across therapeutic areas involving localized gastrointestinal distress. The medication is commonly used to help with the heightened distress of nausea and the physical act of vomiting, and it plays a role in managing symptoms of disorders such as Gastroparesis and Functional Dyspepsia.

Symptom Domains and Therapeutic Benefits

Furol is used to address symptom clusters that may become prominent, such as the uncomfortable sensation of fullness (bloating) and upper abdominal discomfort. It also provides supportive relief when symptoms become temporarily intense, such as during postoperative states or emesis associated with treatments like chemotherapy regimens. The medication assists with maintaining functional stability, which helps ease the overall symptom burden. It is relevant in conditions characterized by periods of heightened symptoms, including certain manifestations of Gastroesophageal Reflux Disease (GERD) and less common occurrences like persistent hiccups.

Quick Fact: Symptom Support Areas

Primary Benefit Supportive Action Contexts of Use
Easing distress from vomiting Supporting the management of symptoms of Gastroparesis Postoperative symptom control
Managing persistent nausea Contributing to the easing of feelings of fullness GERD symptom support

Eligibility and Restrictions for Use

Who Can and Cannot Use Furol?

The population eligibility for Furol (Bromopride) is strictly defined by regulatory documentation, outlining groups for whom use is absolutely prohibited or is conditional.


Absolute Contraindications

Use of Furol is contraindicated in patients with a known hypersensitivity to the drug or its components. It must not be used by individuals with a history of Epilepsy, Convulsions, Parkinsonism, or Feocromocitoma.

Furthermore, the medicine is contraindicated when gastrointestinal motility stimulation is dangerous, specifically in cases of Gastrointestinal Hemorrhage, Mechanical Obstruction, or Perforation.

Age and Comorbidity Restrictions

The drug is contraindicated in children under one year of age. While approved for children ge 1 year, prolonged use must be avoided due to risk of extrapyramidal effects. Use requires caution in the Elderly and in patients with comorbidities like Glaucoma, Diabetes, or Hypertension.

Conditional use is necessary for individuals with Renal or Hepatic Impairment.

Reproductive Limitations

Regulatory guidance advises avoiding use in the first trimester of pregnancy. While breastfeeding, use requires caution due to the potential for the drug to be excreted in breast milk.

What should I know about interactions with other medicines?

Official Documented Interaction Patterns

Furol (Bromopride) interacts with other substances primarily through pharmacodynamic effects on the central nervous system and its impact on gastrointestinal motility, as documented in official regulatory sources. These interactions dictate co-administration restrictions defined in the official prescribing information.

Drug–Drug Interactions

Co-administration with Dopamine Agonists, such as Levodopa, is formally noted as resulting in functional antagonism, which reduces the therapeutic efficacy of the agonist agent. Similarly, Anticholinergic drugs and narcotic analgesics (opioids) functionally oppose Furol's primary action by reducing its prokinetic effect on the digestive tract. The official labeling states that co-administration with CNS depressants—including sedatives, hypnotics, and tranquilizers—results in pharmacodynamic reinforcement, increasing the risk of somnolence.

Exposure and Substance Interactions

Furol's effect on gastrointestinal motility may reduce the absorption of other oral medicines that are primarily absorbed in the stomach, which includes substances such as Digoxin. Official regulatory text mandates the avoidance of alcohol (ethanol) during treatment due to the potential for reinforcing the sedative effects. Regulatory documents also advise using caution when co-administering Furol with Monoamine Oxidase Inhibitors (MAOIs).

Mechanism of Action

Furol (Bromopride) operates through a dual mechanism of action, targeting key receptors in both the brain and the digestive system by modulating emetic and motility pathways. The action is driven by specific molecular interactions that lead to defined physiological changes.


Central Blockade of the Vomiting Reflex

This domain centers on D2 receptor antagonism within the Chemoreceptor Trigger Zone (CTZ) in the brain. By blocking these receptors, the molecule interferes with the ability of circulating chemical signals to activate the brainstem's vomiting center. This action establishes the functional elevation of the emetic threshold, which results in the modulation of the central reflex pathway's response to emetogenic stimuli.


Enhancement of Upper Gastrointestinal Motility

This prokinetic mechanism involves a synergistic action in the gut's enteric nervous system (ENS). The molecule acts as an antagonist at peripheral D2 receptors and an agonist at 5- HT4 receptors, both of which promote the release of Acetylcholine. This increase in cholinergic signaling enhances the strength and coordination of smooth muscle contractions, which facilitates gastric emptying and increases the resting tone of the Lower Esophageal Sphincter.

Dosage and Administration Information

How to Use Furol

Furol (Bromopride) is available for three distinct administration routes: Oral (VO), Intramuscular (IM), and Intravenous (IV), used to accommodate different clinical scenarios. The medication is supplied in oral forms, including tablets, capsules, and liquid solutions, and as injectable solutions for parenteral use. The oral liquid form is often utilized when administering the drug to the pediatric population.

Standard Dosing and Frequency

The administration schedule is structured around a total daily dose which is administered in divided portions throughout the day, rather than in a single dose. For adults using the oral route, the typical total daily dosage is defined to be between 20 to 60 mg. This schedule typically involves taking individual doses before meals and, when appropriate, before bedtime to support continuous action.

Specialized Administration

Parenteral administration is typically reserved for acute situations and requires specific procedural controls. For example, when the intravenous route is selected, clinical protocols generally describe that the injectable solution be diluted and administered slowly, over a period of at least three minutes. Dosing for the pediatric population is determined by a precise body weight-based calculation, and the use of the injectable form is not recommended for prolonged periods.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Research

Research has evaluated this medication for the management of [Condition Name]. The research investigated the medication's effect on [Condition Name] symptoms. Investigators examined whether the treatment related to a reduction in the severity of symptoms, and evaluated whether it was associated with an improvement in quality of life.

  • Study Design: The primary registration trials were double-blind, randomized, and placebo-controlled.
  • Duration: Most studies had a duration of 12 to 16 weeks, with longer-term follow-up in open-label extension studies.

Study Outcome Measures

Studies have investigated the time to symptom change following the initiation of treatment. A key Phase III trial evaluated changes in disease activity over time using the [Specific Metric] score.

Endpoint Observation in Study
Reduction in [Specific Symptom] Examinations found a mean change of X points vs. Y for placebo.
Improvement in Daily Function Evaluations noted a Z% responder rate in the active group.

Comparative and Combination Studies

Research has examined its use among individuals who have difficulty with existing treatments. These studies often compared outcomes against placebo in this specific patient group.

Research has also examined the combination of this medication with [Another Treatment Name]. Investigators evaluated whether it was associated with changes in treatment adherence when compared to [Another Treatment Name] alone. Studies have explored its potential role as a first treatment option.


Safety and Tolerability Profile

Investigators reviewed safety data from long-term extension studies. Trial data listed common adverse events documented in the clinical trials as [AE 1], [AE 2], and [AE 3].

The trials included protocols for monitoring liver function during the treatment period. The research protocols excluded individuals with severe heart conditions due to potential interaction risks identified during non-clinical studies that informed the trial design.

Key Studies & References

  1. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder... (Example Phase III Study on Clinical Trials.gov)
  2. Concise guidance: National Primary Care Treatment and Referral Guidelines for Common Skin Conditions (Example Clinical Guideline for Comparative Use)

Frequently Asked Questions (FAQ)

Common questions about Furol (FAQ)


Q: Are headaches a known side effect of Furol?

Headache is a documented central nervous system adverse effect reported in official regulatory labeling. This indicates that it is an event reported during the clinical development of the medicine. Such effects are sometimes observed with medications that affect the central nervous system.


Q: What is the percentage chance of experiencing the most common side effects of Furol?

Regulatory documents categorize the frequency of side effects (e.g., very common, common, uncommon) based on data gathered from clinical trials. These categories indicate the general likelihood of experiencing an adverse event. However, specific percentage rates are variable and not typically presented for general patient information.


Q: Does Furol cause stomach upset?

Gastrointestinal disturbances, such as abdominal discomfort or changes in bowel habits like diarrhea, are reported adverse effects in the official labeling. The occurrence of such effects may be related to the medicine's action of promoting muscle movement in the digestive system.


Q: Can I take Furol if I have a history of heart problems?

Official documents advise caution and recommend medical monitoring for individuals with pre-existing heart conditions. This is particularly relevant due to the potential risk of an abnormal heart rhythm known as QT interval prolongation, as cited in regulatory warnings.


Q: What are the symptoms of an allergic reaction to Furol?

Severe hypersensitivity reactions are possible with this medication. Official documentation advises that symptoms such as swelling of the face, lips, tongue, or difficulty breathing warrant urgent attention.


Q: Is Furol used to treat anything other than its main approved condition?

Official regulatory approvals indicate that Furol (Bromopride) is indicated for the treatment of nausea and vomiting, and gastroesophageal reflux disease. It is also approved for use as preparation for certain gastrointestinal studies.


Q: What research supports the effectiveness of Furol?

The effectiveness of Furol is supported by data from Phase III clinical trials. These studies were typically double-blind, randomized, and placebo-controlled, providing the evidence basis for the drug's approved indications.


Q: What are the restrictions on driving or operating machinery while taking Furol?

Regulatory documents advise against driving or operating complex machinery. This warning is due to the potential risk of central nervous system effects, such as somnolence (drowsiness) and impaired concentration, that are associated with the medication.


Q: What is the duration of treatment typically recommended for Furol?

Official guidance defines a recommended maximum duration for continuous treatment. This restriction is primarily to mitigate the risk of certain neurological side effects that may be associated with the prolonged use of this class of medication.


Q: Is Furol the same type of medicine as [similar drug name]?

Furol (Bromopride) is categorized as a substituted benzamide, a class of medication. It works primarily as a dopamine D2 receptor antagonist, a mechanism it shares with some other antiemetic and prokinetic agents.


Q: How long does it usually take for Furol to start working?

Pharmacokinetic data from official sources indicates the time it takes for the drug to reach its maximum concentration in the blood. Clinical data suggests the onset of the anti-emetic action can occur within the first hour after the medicine is taken.


Q: Is Furol considered safe to take long-term?

Regulatory bodies advise limiting the duration of treatment. This approach is recommended because official documents cite a potential risk of neurological side effects that may be associated with the prolonged use of this class of medication.


Q: Is there a generic version of Furol available?

The active ingredient, Bromopride, is manufactured as a generic formulation in countries where the medicine is approved. The status as a generic version is noted in international pharmaceutical databases.


Q: Do older adults need a different approach to taking Furol?

Regulatory information advises that the monitoring approach or dosage may require adjustment for older adults. This consideration is due to potential increased physiological sensitivity or the presence of coexisting medical conditions.


Q: Is Furol safe for people who are allergic to penicillin?

Official documentation lists known hypersensitivity to the drug or its components as an absolute contraindication. There is no mention in regulatory sources of a specific cross-allergy between Furol (a substituted benzamide) and penicillin (a beta-lactam).


Q: How long does the effect of one Furol dose typically last?

The general duration of a single dose's action in the body is informed by the drug's elimination half-life. This pharmacokinetic property is defined in official data and is used to determine the frequency of recommended doses.


Q: Is it normal to feel slightly dizzy when starting Furol?

Dizziness is listed in regulatory documentation as a documented central nervous system adverse effect. This indicates it is a documented adverse effect that has been observed in individuals, particularly when initiating treatment.


Q: What happens if I accidentally take two doses of Furol close together?

Official documentation describes potential symptoms of an overdose. These symptoms may include excessive drowsiness, involuntary muscle movements (extrapyramidal reactions), and other neurological changes.


Q: Are there any laboratory tests required before or during treatment with Furol?

Regulatory guidelines may advise on the need for laboratory monitoring of certain bodily functions. This may include monitoring liver enzymes or cardiac function, especially for patients who have pre-existing health conditions.


Q: What is the expiration date on Furol packaging based on?

The expiration date stamped on the packaging is determined by official stability data gathered during the regulatory process. This data guarantees the potency and quality of the medicine until that date, provided it is stored under the specified conditions.


Q: What is the proper way to dispose of unused Furol?

Unused or expired Furol must be disposed of through a dedicated pharmaceutical medicine take-back program. Official regulatory guidance states that it should not be placed in household waste or flushed down wastewater.


Q: Are there different strengths of Furol available?

Furol is manufactured in various dosage forms, such as tablets, oral solutions, and injectable solutions. It is available in different strengths to allow for flexible and age-appropriate administration.


Q: Why do official documents advise caution when using Furol with [known interacting drug class]?

Caution is advised because co-administration can result in specific pharmacological effects. For example, using it with certain sedating agents can lead to the reinforcement of drowsiness, or its effect may be antagonized by other drug classes.


Q: Does Furol affect blood pressure readings?

Regulatory documents list cardiovascular adverse effects. These may include changes in blood pressure, such as a temporary drop in blood pressure (hypotension).


Q: Does Furol affect sleep patterns?

Official labeling lists central nervous system adverse effects, such as drowsiness (somnolence). These effects can influence a patient's overall alertness and sleep patterns.

How should Furol be stored and disposed of?

The storage and disposal of Furol must strictly follow official regulatory requirements to ensure the product remains stable.

Storage Conditions

Furol should be stored at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and kept away from excessive heat and moisture. It is mandatory to store the medicine in its original container and keep it tightly closed.

Some liquid forms may have an in-use shelf-life limit and must be discarded if they appear discolored or contain visible particles. Use of the medicine after the expiry date is prohibited.

Disposal and Safety

Regulatory agencies require that this medicine be kept out of the sight and reach of children.

Unused or expired Furol must not be thrown into wastewater or household waste. Disposal should be managed through an official pharmaceutical medicine take-back program or as directed by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furol found in:

A-Z Index: